Editorial: New insights into cancer immunology of refractory GU and liver tumors: therapy and mechanism.
作者信息
Liu Miao
机构信息
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
出版信息
Front Immunol. 2024 May 1;15:1420381. doi: 10.3389/fimmu.2024.1420381. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: New insights into cancer immunology of refractory GU and liver tumors: therapy and mechanism.
Front Immunol. 2024 May 1;15:1420381. doi: 10.3389/fimmu.2024.1420381. eCollection 2024.
2
Editorial: Overcoming the Immune Microenvironment of Hepatocellular Cancer.
Front Immunol. 2021 Jun 2;12:707329. doi: 10.3389/fimmu.2021.707329. eCollection 2021.
3
The interaction of anticancer therapies with tumor-associated macrophages.
J Exp Med. 2015 Apr 6;212(4):435-45. doi: 10.1084/jem.20150295. Epub 2015 Mar 9.
4
Immunotherapy in lymphoma.
Hematol Oncol. 2017 Jun;35 Suppl 1:88-91. doi: 10.1002/hon.2408.
5
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
J Exp Clin Cancer Res. 2019 Sep 9;38(1):396. doi: 10.1186/s13046-019-1396-4.
6
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
J Immunother Cancer. 2019 Oct 18;7(1):267. doi: 10.1186/s40425-019-0749-z.
7
Tumor regulation of the tissue environment in the liver.
Pharmacol Ther. 2017 May;173:47-57. doi: 10.1016/j.pharmthera.2017.02.005. Epub 2017 Feb 4.
8
Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
World J Gastroenterol. 2018 Aug 21;24(31):3500-3512. doi: 10.3748/wjg.v24.i31.3500.
9
Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
OMICS. 2020 Apr;24(4):175-179. doi: 10.1089/omi.2020.0019. Epub 2020 Mar 13.
10
Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
World J Gastroenterol. 2018 May 7;24(17):1839-1858. doi: 10.3748/wjg.v24.i17.1839.
本文引用的文献
1
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.
BMC Cancer. 2023 Aug 29;23(1):810. doi: 10.1186/s12885-023-11298-z.
2
High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.
Cell Death Dis. 2022 Nov 4;13(11):924. doi: 10.1038/s41419-022-05375-7.
3
Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.
Cancer Res. 2021 Dec 1;81(23):6018-6028. doi: 10.1158/0008-5472.CAN-21-0030. Epub 2021 Sep 30.
4
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Front Pharmacol. 2021 Sep 1;12:731798. doi: 10.3389/fphar.2021.731798. eCollection 2021.
5
Next generation of immune checkpoint inhibitors and beyond.
J Hematol Oncol. 2021 Mar 19;14(1):45. doi: 10.1186/s13045-021-01056-8.
6
Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population.
Clin Genitourin Cancer. 2011 Sep;9(1):46-52. doi: 10.1016/j.clgc.2011.04.004. Epub 2011 Jun 22.
7
Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Aktuelle Urol. 2010 Jan;41 Suppl 1:S34-40. doi: 10.1055/s-0029-1224657. Epub 2010 Jan 21.
Zotero 插件